Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET
Company Participants
Sara Pellegrino – Senior Vice President, Investor Relations and Corporate Communications
Fred Vogt – Interim Chief Executive Officer and President
Brian Gastman – Executive Vice President-Medical Affairs
Igor Bilinsky – Chief Operating Officer
Jean-Marc Bellemin – Chief Financial Officer
Friedrich Graf Finckenstein – Chief Medical Officer
Conference Call Participants
Tyler Van Buren – TD Cowen
Peter Lawson – Barclays
Andrea Newkirk – Goldman Sachs
Yanan Zhu – Wells Fargo
Ben Burnett – Stifel
David Dai – UBS
Michael Yee – Jefferies
Asthika Goonewardene – Truist Securities
Operator
Thank you for standing by. My name is Mandeep and I’ll be your operator today. I’d like to welcome everyone to the Iovance Third Quarter 2024 Financial Results Call.
I would now like to turn the call over to Sara.
Sara Pellegrino
Thank you, operator. Good afternoon, and thank you for joining this conference call and webcast to discuss our third quarter and year-to-date 2024 financial results, as well as recent corporate and development program updates.
Dr. Fred Vogt, our Interim Chief Executive Officer and President will provide an introduction and summarize the latest progress with our U.S. Commercial launch of Amtagvi, including revenue and revenue guidance, patient demand and market access, an update on our global regulatory submissions and a high level summary of our key pipeline. Dr. Brian Gastman, our Executive Vice President, Medical affairs, will highlight adoption and demand at authorized treatment centers or ATCs as well as our community outreach initiatives to drive additional growth for the U.S. commercial launch of Amtagvi in advanced melanoma. Dr. Igor Bilinsky, our Chief Operating Officer, will cover our commercial manufacturing experience and the status of our ongoing capacity expansion. Jean-Marc Bellemin, our Chief Financial Officer, will review our financial results including revenue and revenue guidance, gross margin and the strength of our balance sheet. And Dr. Friedrich
Read the full article here
